611 W. Union Street
Benson, AZ 85602
(520) 586-0800

Health Choice Integrated Care crisis Line
1-877-756-4090

NurseWise 24-Hour Crisis Line
1-866-495-6735

NAZCARE Warm Line
1-888-404-5530



SEABHS
611 W. Union Street
Benson, AZ 85602
(520) 586-0800

NurseWise 24-Hr Crisis Line
1-866-495-6735

NAZCARE Warm Line
1-888-404-5530


powered by centersite dot net

Getting Started
Here are some forms to get started. These can be printed and brought with you so that you can pre-fill out some known info ahead of time. More...


Health Sciences
Resources
Basic InformationLatest News
Whole-Genome Sequencing of Uncertain Clinical UtilityCould Shift Work Damage Your DNA?Gene Sequencing May Reveal Risks for Rare DiseasesRogue Genes May Cause Some ALS CasesSticky Brain 'Plaques' Implicated in Alzheimer's AgainEven Your Bones Can Get Fat, Mouse Study SuggestsDoes a Low-Fat Dairy Habit Boost Parkinson's Risk?MicroRNA Biomarker Signature Identified for Allergic AsthmaHaywire Immune Cells May Help Cause BaldnessRegion in Brain Associated With Fear of Uncertain FutureBrain Scans Spot Where Fear and Anxiety LiveGene Therapy Might Someday Mend Badly Broken BonesLife Expectancy Slighter Shorter With Parkinson's, DementiaStudy Looks at Parkinson's Effect on Life SpanBody Cooling May Help Brain After Cardiac ArrestDo You Overeat? Your Brain Wiring May Be WhyGene Mutation May Speed Alzheimer's DeclineIs This Enzyme Making You Fat?Type 2 Diabetes May Be Bad for Brain Health'Brain Age' May Help Predict When You'll DieParkinson's Disease May Originate in Gut, Study SaysBlood-Based Genome Testing Feasible for Rapid Mutation AssayBlood Test May Gauge Death Risk After Surgery150-Year-Old Drug May Shorten 'Off' Time for Parkinson's PatientsBrain May Be Organized by Functions, Not Body PartsBody Temperature Might Give Clues to ComaCould Young Blood Boost the Aging Brain?A 'Brainwave' to Help Fight PTSDDizziness in Parkinson's May Be Due to Cerebral HypoperfusionMisunderstood Gene Tests May Lead to Unnecessary MastectomiesScientists Extend Lives of Mice With ALSFDA Approves 1st Direct-to-Consumer Genetic Risk TestsFDA OKs 1st At-Home Genetic Tests for 10 Disorders'SuperAgers' Have Less Whole-Brain Cortical Volume LossHigh Thyroid Hormone Levels Tied to Stiffer ArteriesBrain Changes May Mark Risk of Financial Exploitation in SeniorsRegular Exercise Slows Decline Even in Advanced Parkinson's DzBrain-Computer Link Restores Some Movement to Quadraplegic ManScientists Spot Gene for Rare Disorder Causing Deafness, BlindnessNew Technology Makes Gene Mapping Cheaper, Faster: StudyTurning Back the Aging Clock -- in MiceNew Parkinson's Drug Xadago ApprovedBrain 'Rewires' to Work Around Early-Life BlindnessBrain Training for Cancer Survivors' Nerve DamageASA: Vagus Nerve Stimulation May Enhance Stroke RecoveryGene Therapy: A Breakthrough for Sickle Cell Anemia?Gene Therapy Shows Promise for Aggressive LymphomaThe Brain Can Produce Its Own Sugar: ReportCould Parkinson's Disease Raise Stroke Risk?NHL Veterans Pledge Their Brains to Research
Questions and AnswersLinksBook Reviews
Related Topics

Medical Disorders
Mental Disorders
Mental Health Professions

Blood-Based Genome Testing Feasible for Rapid Mutation Assay


HealthDay News
Updated: Apr 26th 2017

new article illustration

WEDNESDAY, April 26, 2017 (HealthDay News) -- A blood-based genome testing service provides accurate results within 72 hours, according to a study published online April 19 in the Journal of Molecular Diagnostics.

Hestia Mellert, Ph.D., from Biodesix Inc., in Boulder, Colorado, and colleagues validated a blood-based genome testing service by focusing on targetable variants in advanced non-small-cell lung carcinoma: epidermal growth factor gene (EGFR) variant L858R, exon 19 deletion and T790M; GTPase Kirsten ras gene (KRAS) variants G12C/D/V; and echinoderm microtubule associated protein like and 4 anaplastic lymphoma receptor tyrosine kinase fusion (EML4-ALK) transcripts 1/2/3. Test development and clinical validation were performed on samples from 219 donors with and 30 without cancer.

The researchers found that for each variant, the clinical sensitivity ranged from 78.6 to 100 percent, and specificity ranged from 94.2 to 100 percent. Results were also available for 1,643 non-small-cell lung carcinoma samples, with mutation results available within 72 hours for 94 percent of tests evaluated. Overall, 10.5, 13.8, 13.2, and 2 percent of mutations were detected for EGFR sensitizing, EGFR resistance, KRAS, and EML4-ALK fusion, respectively.

"This rapid, highly sensitive, and actionable blood-based assay service expands testing options and supports faster treatment decisions," the authors write.

Several authors disclosed financial ties to Biodesix Inc., which funded the study. Several authors are co-inventors on a patent application filed by Biodesix, covering a diagnostic test system for the detection of circulating genetic variants in non-small-cell lung cancer.

Abstract
Full Text